Literature DB >> 26597819

Vascular Matrix Metalloproteinase Inhibition, a New Mechanism for How Peroxisome Proliferator-Activated Receptor-γ Protects Target Organ Damage.

Steven J Forrester1, Satoru Eguchi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26597819      PMCID： PMC4679578          DOI： 10.1161/HYPERTENSIONAHA.115.06532

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  11 in total

Review 1.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 2.  The history of matrix metalloproteinases: milestones, myths, and misperceptions.

Authors:  Rugmani Padmanabhan Iyer; Nicolle L Patterson; Gregg B Fields; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-17       Impact factor: 4.733

3.  Myocardial recovery from ischemia-reperfusion is compromised in the absence of tissue inhibitor of metalloproteinase 4.

Authors:  Abhijit Takawale; Dong Fan; Ratnadeep Basu; Mengcheng Shen; Nirmal Parajuli; Wang Wang; Xiuhua Wang; Gavin Y Oudit; Zamaneh Kassiri
Journal:  Circ Heart Fail       Date:  2014-05-19       Impact factor: 8.790

4.  TIMP-4 is regulated by vascular injury in rats.

Authors:  C M Dollery; J R McEwan; M Wang; Q A Sang; Y E Liu; Y E Shi
Journal:  Circ Res       Date:  1999-03-19       Impact factor: 17.367

Review 5.  Treatment of arterial remodeling in essential hypertension.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

6.  TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension.

Authors:  Ratnadeep Basu; Jiwon Lee; Jude S Morton; Abhijit Takawale; Dong Fan; Vijay Kandalam; Xiuhua Wang; Sandra T Davidge; Zamaneh Kassiri
Journal:  Cardiovasc Res       Date:  2013-03-21       Impact factor: 10.787

7.  Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.

Authors:  Utpal Sen; Walter E Rodriguez; Neetu Tyagi; Munish Kumar; Soumi Kundu; Suresh C Tyagi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-09       Impact factor: 4.310

8.  Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling.

Authors:  Stéphanie Lehoux; Catherine A Lemarié; Bruno Esposito; H Roger Lijnen; Alain Tedgui
Journal:  Circulation       Date:  2004-02-16       Impact factor: 29.690

Review 9.  Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology.

Authors:  Sadaharu Higuchi; Haruhiko Ohtsu; Hiroyuki Suzuki; Heigoro Shirai; Gerald D Frank; Satoru Eguchi
Journal:  Clin Sci (Lond)       Date:  2007-04       Impact factor: 6.124

Review 10.  Tissue inhibitor of metalloproteinases-4. The road less traveled.

Authors:  Jorge Melendez-Zajgla; Luis Del Pozo; Gisela Ceballos; Vilma Maldonado
Journal:  Mol Cancer       Date:  2008-11-21       Impact factor: 27.401
View more
  2 in total

1.  Downregulating long non-coding RNA PVT1 expression inhibited the viability, migration and phenotypic switch of PDGF-BB-treated human aortic smooth muscle cells via targeting miR-27b-3p.

Authors:  Shouming Li; Xin Zhao; Shaopeng Cheng; Jialiang Li; Xiao Bai; Xiangbin Meng
Journal:  Hum Cell       Date:  2020-10-26       Impact factor: 4.174

2.  Regulation of Pancreatic Fibrosis by Acinar Cell-Derived Exosomal miR-130a-3p via Targeting of Stellate Cell PPAR-γ.

Authors:  Qiang Wang; Hao Wang; Qingxu Jing; Yang Yang; Dongbo Xue; Chenjun Hao; Weihui Zhang
Journal:  J Inflamm Res       Date:  2021-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.